Unum Therapeutics Inc (NASDAQ:UMRX) has received an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $14.60.
Several research analysts have issued reports on UMRX shares. Cowen started coverage on Unum Therapeutics in a research report on Tuesday, February 26th. They issued a “market perform” rating on the stock. Zacks Investment Research cut Unum Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. SunTrust Banks lowered their price objective on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a research report on Friday, March 29th. They noted that the move was a valuation call. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Unum Therapeutics in a research report on Friday, March 29th.
NASDAQ:UMRX traded up $0.02 on Wednesday, hitting $3.58. The stock had a trading volume of 636 shares, compared to its average volume of 60,020. The stock has a market capitalization of $107.12 million and a price-to-earnings ratio of -2.59. Unum Therapeutics has a 52-week low of $3.30 and a 52-week high of $17.66.
In other news, insider Seth Ettenberg sold 11,485 shares of Unum Therapeutics stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $4.12, for a total transaction of $47,318.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
A number of institutional investors and hedge funds have recently modified their holdings of UMRX. American International Group Inc. raised its stake in Unum Therapeutics by 432.8% during the 4th quarter. American International Group Inc. now owns 12,531 shares of the company’s stock valued at $55,000 after purchasing an additional 10,179 shares during the period. Jane Street Group LLC bought a new stake in Unum Therapeutics during the 3rd quarter valued at approximately $150,000. Bank of New York Mellon Corp raised its stake in Unum Therapeutics by 251.5% during the 4th quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after purchasing an additional 33,091 shares during the period. JPMorgan Chase & Co. raised its stake in Unum Therapeutics by 2,782.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after purchasing an additional 20,033 shares during the period. Finally, Citadel Advisors LLC bought a new stake in Unum Therapeutics during the 3rd quarter valued at approximately $235,000. 47.42% of the stock is currently owned by institutional investors.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More: What is a support level?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.